Detalhe da pesquisa
1.
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
N Engl J Med
; 388(15): 1353-1364, 2023 Apr 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36876740
2.
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
JAMA
; 331(1): 38-48, 2024 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38078870
3.
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
N Engl J Med
; 380(11): 1022-1032, 2019 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30865796
4.
Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials.
Diabetes Obes Metab
; 24(5): 868-880, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34981622
5.
Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance.
Am Heart J
; 235: 104-112, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33470195
6.
Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.
Cardiovasc Drugs Ther
; 32(2): 181, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29713852
7.
Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials.
Cardiovasc Drugs Ther
; 32(2): 175-180, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29627892
8.
Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies.
Prostaglandins Other Lipid Mediat
; 125: 57-64, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27418543
9.
Icosabutate, a Structurally Engineered Fatty Acid, Improves the Cardiovascular Risk Profile in Statin-Treated Patients with Residual Hypertriglyceridemia.
Cardiology
; 135(1): 3-12, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27160246
10.
Colesevelam, Ezetimibe, and Patients With Type 2 Diabetes Mellitus: Characteristics and Clinical Outcomes From a Health Care Database.
Ann Pharmacother
; 48(7): 847-855, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24740470
11.
Effects of phentermine / topiramate extended-release, phentermine, and placebo on ambulatory blood pressure monitoring in adults with overweight or obesity: A randomized, multicenter, double-blind study.
Obes Pillars
; 9: 100099, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38304225
12.
Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance.
J Clin Lipidol
; 18(1): e59-e69, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-37951797
13.
Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
Cardiovasc Diabetol
; 12: 100, 2013 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-23835245
14.
The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.
Nat Med
; 29(7): 1782-1792, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37355760
15.
Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials.
Atherosclerosis
; 373: 1-9, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37075696
16.
Obesity definition, diagnosis, bias, standard operating procedures (SOPs), and telehealth: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.
Obes Pillars
; 1: 100004, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37990702
17.
Corrigendum to "Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022" [Obes Pillars 2 (2022) 100018].
Obes Pillars
; 4: 100035, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37990671
18.
Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.
Obes Pillars
; 2: 100018, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37990711
19.
Obesity history, physical exam, laboratory, body composition, and energy expenditure: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.
Obes Pillars
; 1: 100007, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37990700
20.
Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering With Bempedoic Acid.
J Am Heart Assoc
; 11(15): e024531, 2022 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35916348